Evidence map›Paper›PMID 42130226›Full record

Observational studyJournal of surgical oncology2026

Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.

Camille C Baumrucker, Nicole Harris, Paige Aiello, Junmin Whiting, Weihong Sun, Hatem Soliman, Hyo Han, Ricardo Costa, Brian J Czerniecki, Marie Catherine Lee

5 registry-linked trialsAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01042379 phase2recruitingnot on this map

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

TypeinterventionalSponsorQuantumLeap Healthcare CollaborativeRan2010 to 2031Enrolled5,000ConditionsBreast Neoplasms, Breast Cancer, Breast Tumors, AngiosarcomaArmsStandard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab
NCT02779855 phase1 / phase2completednot on this map

A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

TypeinterventionalSponsorH. Lee Moffitt Cancer Center and Research InstituteRan2017 to 2025Enrolled50ConditionsBreast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast CarcinomaArmsTalimogene laherparepvec, Paclitaxel
NCT03387553 early_phase1completednot on this map

A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer

TypeinterventionalSponsorH. Lee Moffitt Cancer Center and Research InstituteRan2018 to 2026Enrolled31ConditionsBreast Cancer, Breast Cancer Female, Breast Cancer, Male, Invasive Breast CancerArmsDendritic Cell Vaccine (DC1), Neoadjuvant Chemotherapy, Curative Surgery
NCT05325632 phase2recruitingnot on this map

A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed Dendritic Cell (DC1) Vaccine Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer

TypeinterventionalSponsorH. Lee Moffitt Cancer Center and Research InstituteRan2021 to 2027Enrolled53ConditionsHER2-positive Breast CancerArmsHER-2 pulsed DC1, Trastuzumab, Pertuzumab, Paclitaxel, Resection surgery
NCT05504707 phase1recruitingnot on this map

Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

TypeinterventionalSponsorH. Lee Moffitt Cancer Center and Research InstituteRan2022 to 2026Enrolled30ConditionsTriple Negative Breast Cancer, HER2-negative Breast CancerArmsHER2 - primed Dendritic cells, HER3 - primed Dendritic cells
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Camille C BaumruckerDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.ORCID https://orcid.org/0000-0002-8920-0732
Nicole HarrisDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Paige AielloDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Junmin WhitingDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Weihong SunDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Hatem SolimanDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Hyo HanDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Ricardo CostaDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Brian J CzernieckiDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
Marie Catherine LeeDepartment of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunotherapy is a growing treatment option for challenging breast cancer (BC) subtypes. Systemic administration can have significant adverse events (AEs), prompting interest in intratumoral injection. We evaluated the safety and feasibility of intratumoral injections at our institution.

methodsThis is an IRB-approved retrospective review of neoadjuvant patients who received intratumoral talimogene laherparepvec (TVEC) (NCT02779855) for triple negative breast cancer (TNBC), dendritic cells (DC1) for HER2+ (NCT05325632), HER2 + /ER- (NCT03387553), or TNBC (NCT05504707), or Voyager V1 virus (VV1) (NCT01042379) for high-risk lesions on ISPY2. This study outlines the safety and feasibility of intratumoral injections assessed by AEs, adherence to therapy, and ultrasound guidance.

resultsThe study included 111 female patients (mean age 51; range 26-80). Forty-seven (42.3%) received TVEC, 62 (55.9%) received DC1, and 2 (1.8%) received VV1. Three patients missed one injection; 110 patients had ultrasound-guided injections. Mean neoadjuvant therapy length was 172 days (range 127-244). Local AEs included pain (20.7%), injection site reaction (27.9%), and hematoma (5.4%). Systemic AEs were reported more frequently, most commonly chills (52.3%), headache (39.6%), and fever (36.8%). DISCUSSION: Intratumoral IT injection is a viable treatment option that may minimize systemic exposure while maintaining therapeutic efficacy. Breast surgeons can play a role in intratumoral IT in BC.

Indexed as

Antineoplastic Agents, ImmunologicalBreast NeoplasmsImmunotherapyTriple Negative Breast NeoplasmsAdultAgedAged, 80 and overBiological ProductsDendritic CellsFemaleHerpesvirus 1, HumanHumansInjections, IntralesionalMiddle AgedOncolytic VirotherapyRetrospective StudiesAntineoplastic Agents, ImmunologicalBiological Productstalimogene laherparepvecbreast immunotherapydendritic cellsintratumoral injectiononcolytic virus

Identifiers

PMID42130226
PMCPMC13427119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.